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Background/Purpose: About one-half of metastatic colorectal cancer (MCRC) patients are 70 years of
age. There is uncertainty regarding the beneﬁt patients derive from advanced chemotherapy lines. In this
study, we aim to evaluate the efﬁcacy and safety of third-line chemotherapy treatments among MCRC
patients.
Methods: Consecutive patients 70 years or older at the time of diagnosis of metastatic disease who
received third-line chemotherapy at the Tel-Aviv Sourasky Medical Center between the years 2000e2009
were collected. Data on demographics, stage of disease, treatment lines and oncological outcomes were
extracted from their medical ﬁles.
Results: Only 34 out of 63 patients (54%) available patients received third-line treatments. The (median)
age of all patients, third-line patients and the remaining patients, were similar (74.5, 74 and 75.3 years,
respectively, P ¼ NS). Following third-line treatments, only 9% had a partial response, and the disease
was stable in 29% of patients seen. Thirteen weeks is the median duration of third-line treatments. Only
three patients had symptomatic relief. Importantly, 15 patients (44%) required dose reduction or treat-
ment delay due to toxicity (neutropenia or thrombocytopenia). The median survival (mOS) is 9 months
for patients with ﬁrst-line treatment, 19 months for second-line treatment and 37 months for third-line
treatment (Log Rank < 0.0001). There was a signiﬁcant association between the number of lines of
treatment and the mOS (P ¼ 0.0001).
Conclusion: Third-line chemotherapy treatment of elderly MCRC patients was associated with a minor
clinical response, a considerable number of side effects, but a longer survival rate. Third-line chemo-
therapy in ﬁt elderly patients should be pursued, however, protocols must be adjusted before third-line
treatment is implemented.
Copyright © 2015, Asia Paciﬁc League of Clinical Gerontology & Geriatrics. Published by Elsevier Taiwan
LLC.  Open access under CC BY-NC-ND license.1. Introduction
Colorectal cancer (CRC) is the fourth most commonly diag-
nosed cancer in men and women, with >1,200,000 new cases
detected each year and >600,000 deaths/y worldwide.1 Approxi-
mately one half of the patients are aged  70 years. Survival ofastrointestinal Tract Malignancies C
erms of the Creative Commons At
ribution, and reproduction in any
linical Gerontology & Geriatrics. Ppatients has improved considerably in the last 2 decades. As the
world population ages, a greater number of elderly patients will
require treatment. One ﬁfth to a quarter of all newly diagnosed
patients have Stage 4 disease, whereas one third of all early stage
patients will develop recurrent metastatic disease. The goals of
chemotherapy for patients with metastatic CRC (MCRC) are toenter, Tel Aviv Sourasky Medical Center, 6 Weizman Street, Tel Aviv 6423906, Israel.
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improve patients' quality of life. Palliative chemotherapy is now
offered to an increasing proportion of patients with advanced
MCRC. There is no universally accepted standard therapy or route
of administration as such, and the current main treatment for
metastatic disease is systemic chemotherapy, with or without, a
biologically targeted agent. This treatment yields a median sur-
vival of 2e3 years.1,2
There is some uncertainty regarding the beneﬁts elderly pa-
tients receive from adjuvant or palliative chemotherapy, and the
extent to which it should be used.3e5 There are many factors that
inﬂuence treatment decisions, such as performance status, co-
morbidity, family or social support, mental status and compliance,
physiologic age, and others.3,4,6 Older patients are also more
prone to develop treatment-related toxicity, especially
myelotoxicity.3,4,6
Moreover, patients who are aged  70 years typically do not
exceed 15e20% of the studied populations in clinical trials, making
it difﬁcult to extrapolate the results of these trials when solely
applying them to older patients.
Patients with MCRC will be given a greater number of treatment
lines the longer they survive. There is a large body of evidence
regarding the treatment of elderly MCRC patients in the adjuvant
setting3,4,6 and with ﬁrst- and second-line treatments4,5 for meta-
static disease. This analysis was aimed to retrospectively evaluate
the efﬁcacy and safety of third-line treatments for MCRC among
patients aged  70 years.
2. Methods
2.1. Study population
The study population included consecutive MCRC patients who
were aged  70 years at the time of diagnosis of metastatic disease
and those who received third-line chemotherapy treatments at the
Tel Aviv Sourasky Medical Center between 2000 and 2009. Data on
patients' age, sex, stage of disease, and treatment at the initial
diagnosis stage were retrospectively extracted from their medical
ﬁles. The data pertaining to treatment for metastatic disease
included regimens of chemotherapy used for the three different
lines of treatment, duration of treatment in weeks, and whether or
not there were interruptions in treatment. The response to treat-
ment was evaluated using Response Evaluation Criteria in Solid
Tumor 0.1 (RECIST 0.1). Symptom relief and side effects were also
recorded from the patients' medical ﬁles. Overall survival was
calculated from the ﬁrst diagnosis of the existing metastatic
disease.
The Charlson Comorbidity Index7 was used to score the pa-
tients' comorbidity, which was calculated from the patients'
medical records, after exclusion of the diagnosis of colorectal
carcinoma.
The Charlson Comorbidity Index is the most frequently used
comorbidity scoring system in clinical trials. It was initially con-
structed from a longitudinal analysis of 559 individuals admitted to
a medical service.7 Twenty associated conditions, shown to have a
1-year relative risk of death, were given aweighted value relative to
their potential impact. This index has been validated for predicting
major complications in many malignancies, including patients with
CRC.8,9
2.2. Statistical analysis
Parameters of survival were analyzed using Cox regression and
demonstrated by KaplaneMeier curves. Associations between
median survival times of various subgroups were analyzed usingthe ManneWhitney test. Statistical analyses (statistical signiﬁcance
was deﬁned by an alpha of 0.05) were performed using SPSS soft-
ware (SPSS Inc., Chicago, IL, USA).
3. Results
A total of 63 consecutive MCRC patients who were aged  70
years were included in this trial. Most of them (n ¼ 57, 90%)
received at least ﬁrst-line treatments, 45 (71%) received second-
line treatments, and 34 (54%) received third-line treatments. The
(median) age of all patients, patients receiving third-line chemo-
therapy treatments, and the remaining patients was 74.5 years, 74
years, and 75.3 years, respectively (p ¼ not signiﬁcant). Of the total
study patients, 38 (60%) were men and 25 (40%) were women.
More male patients than female patients received third-line
treatments (68% vs. 32%, respectively; p < 0.05). Characteristics
of the patients are summarized in Table 1. The decrease in treated
populations across the different lines of treatment is depicted in
Fig. 1.
3.1. Stage of disease at ﬁrst diagnosis
Seventy-one percent of patients had Stage 4 disease at ﬁrst
diagnosis. Therewas no signiﬁcant association between the stage at
ﬁrst diagnosis and the probability of receiving third-line treatment.
3.2. First-line treatment for metastatic disease
The treatment lines used for the 57 patients who received ﬁrst-
line treatments for MCRC are described in Table 2. There was no
association between the medication that was administered for the
ﬁrst-line treatment and that used for third-line treatment. The
median treatment duration for the whole group was 20 weeks. The
median duration of ﬁrst-line treatment was longer among patients
who went on to receive third-line treatments compared with those
who did not receive third-line treatments (23 weeks vs. 12 weeks,
respectively, p < 0.05).
Twenty-ﬁve of the 57 patients (44%) who received ﬁrst-line
treatments were given an irinotecan-based regimen, 12 patients
(21%) were given an oxaliplatin-based regimen, and 22 patients
(39%) received an additional targeted therapy (mainly bev-
acizumab). There was no association between the ﬁrst-line treat-
ment regimen and the probability of receiving third-line treatment.
Response to treatment was evaluated in 44 patients: it was partial
for 13 patients (30%, from evaluated patients), the condition
remained stable in 12 patients (27%), and there was disease pro-
gression in 19 patients (43%). There was no signiﬁcant association
between the response to ﬁrst-line treatments and subsequent
second- or third-line treatments, although numerically, more pa-
tients who responded to the ﬁrst-line treatments received third-
line treatments, compared with those whose disease progressed
after their ﬁrst-line treatment. The median duration of ﬁrst-line
treatments was 20 weeks, and it was longer among patients who
later received third-line treatments compared with those who did
not receive third-line treatments (21 weeks vs. 12 weeks, respec-
tively, p ¼ 0.0347).
3.3. Second-line treatment for metastatic disease
Forty-ﬁve patients (71%) received second-line treatments that
consisted of an irinotecan-based regimen (16 patients, 36%), an
oxaliplatin-based regimen (21 patients, 47%), or an additional tar-
geted therapy (14 patients, 31%). There was no association between
the second-line treatment regimen and the probability of receiving
third-line treatments. Therapeutic response was evaluated in 31
Table 1
Patients characteristics.
No. of patients Median age at diagnosis (y) Sex of the patient, n (%) Stage at ﬁrst diagnosis, n (%) CCI, n (%)
All patients 63 74.5 Male, 38 (60)
Female, 25 (40)
Stage 4, 45 (70) CCI 0, 29 (46)
CCI 1, 21 (33%)
CCI 2, 9 (15)
CCI 3, 4 (6)
Third-line-treated patients 34 74 Male, 26 (76)
Female, 8 (24)
Stage 4, 27 (79)
Stage 3, 3 (9)
Stage 2, 3 (9)
Stage NA, 1 (3)
CCI 0, 15 (44)
CCI 1, 14 (41)
CCI 2, 4 (12)
CCI 3, 1 (3)
No third-line treatment 29 75.3 Male, 12 (41)
Female, 17 (59)
Stage 4, 18 (62)
Stage 3, 6 (21)
Stage 2, 5 (17)
CCI 0, 14 (48)
CCI 1, 7 (24)
CCI 2, 5 (18)
CCI 3, 3 (10)
(10)
CCI¼ Charlson Comorbidity Index; NA ¼ not available.
Fig. 1. Percentage of patients across the different treatment lines. The data presented show a decrease from 90% at the ﬁrst line to 71% and 54% in the second and third lines,
respectively.
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tients), the disease remained stable in 15 patients (48%), and there
was disease progression in 13 patients (42%). There was no signif-
icant association between the response to the second-line treat-
ment and patients who received third-line treatments later on,
although numerically, more patients who responded to the second-
line treatment received third-line treatments compared with those
patients whose disease progressed on their second-line treatment.
The median duration of second-line treatment was 18 weeks, and it
was longer among patients who later received third-line treat-
ments compared with those who did not receive third-line treat-
ments (20 weeks vs. 7 weeks, respectively, p ¼ 0.0129).
3.4. Third-line treatment for metastatic disease
A total of 34 patients (54%) received third-line treatments that
consisted of an irinotecan-based regimen for 13 patients (38%), an
oxaliplatin-based regimen for 11 patients (32%), and an additional
targeted therapy for 13 patients (38%). There was no association
between the second-line treatment regimen and the probability ofTable 2
Treatment lines combinations.
Treatment line for
MCRC
Patients Oxaliplatin þ
ﬂuoropyrimidine
Irinotecan þ
ﬂuoropyrimid
First line 57 (90) 12 (21) 25 (44)
Second line 45 (71) 21 (45) 16 (36)
Third line 34 (54) 11 (32) 13 (38)
Data are presented as n (%).
MCRC ¼ metastatic colorectal cancer.receiving third-line treatments. The therapeutic response was
evaluated in 29 patients: it was partial in three patients (10%), the
disease remained stable in 10 patients (34%, from evaluated pa-
tients), and there was disease progression in 16 patients (55%). The
median duration of third-line treatment was 13 weeks. Twenty-
two patients (65%) were symptomatic at the start of the third-
line treatment, 10 patients (29%) were asymptomatic, and there
were two patients with missing information. Only three patients
had symptomatic relief from third-line treatment. Toxicity of third-
line treatments required dose reduction or treatment delays in 15
patients (44%). The most common side effects were general
weakness (n ¼ 23, 68%), diarrhea (n ¼ 15, 44%), and neutropenia
(n ¼ 8, 24%).
3.5. Survival data
At the time of data collection, eight patients were still alive and
three had been lost to follow up. The median survival rate since the
ﬁrst diagnosis was 28 months. Patients who only had ﬁrst-line
treatment had a median survival of 9 months, those with second-ine
Fluoropyrimidine
only
Chemotherapy þ
bevacizumab
Chemotherapy þ
cetuximab
16 (28) 21 (37) 1 (2)
5 (11) 9 (20) 5 (11)
6 (2) 2 (6) 11 (32)
Fig. 2. Overall survival according to the number of treatment lines for metastatic disease. Patients receiving three lines of treatment had clearly better overall survival compared
with patients receiving one or two lines of treatment (p ¼ 0.0001).
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received third-line treatment had a median survival of 37 months
(log rank < 0.0001; Fig. 2). The median survival since the ﬁrst
diagnosis of metastases was 23 months. Patients who had received
only ﬁrst-line treatment had a median survival of 7 months, those
who were treated with second-line treatment had a median sur-
vival of 16 months, and those who received third-line treatment
had a median survival of 35 months (log rank < 0.0001; Fig. 2).
There was a signiﬁcant association between the number of treat-
ment lines andmedian overall survival (p¼ 0.0001). There was also
a signiﬁcant association between the lack of response to the ﬁrst-
line treatment and a worse median overall survival. Patients who
had progression of disease during the ﬁrst-line treatment had a
shorter survival rate than patients who had responsive or stable
disease (p ¼ 0.0014, Fig. 3). There were no differences between the
patients' response to the second- and third-line treatments and
survival or in the association between the choice of chemotherapy
combination and the length of survival.0.00
0.25
0.50
0.75
1.00
Su
0 500 1000 1500
f
Fig. 3. Overall survival based on the response to ﬁrst-line treatment. Patients who had prog
had responsive or stable disease (p ¼ 0.0014).4. Discussion
The median survival of elderly CRC patients is shorter than that
of younger patients.7 This might be due to a number of reasons,
such as comorbidity and decreased performance status. It may also
be attributed to the undertreatment of older patients as a group.
Jessup et al9 reported that the use of adjuvant chemotherapy
differed considerably by age: adjuvant chemotherapy was used in
82% of patients aged < 60 years, 77.2% of patients aged between 60
years and 69 years, 69% of patients aged between 70 years and 79
years, and only 39.2% of patients aged 80 years. In addition, Dobie
et al10 noted that when adjuvant chemotherapy was used, the
chance of treatment termination before the completion of planned
full dose was higher among the elderly patients. This trend of
undertreatment of the elderly patients is also evident in the met-
astatic disease setting, as well as in the use of doublets (irinotecan-
or oxaliplatin-based regimens) and triplets (adding a biological
agent).11rvival (d)
2000 2500 3000 3500
___ Progressive disease  
___ ParƟal response 
___ Stable disease  
ression of disease during ﬁrst-line treatment had a shorter survival than patients who
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treatment in elderly patients. As expected, the median treatment
duration was shortened as more treatment lines were used (20
weeks, 18 weeks, and 13 weeks for ﬁrst, second, and third line,
respectively). The duration of ﬁrst-line treatment in our analysis
was shorter than that reported in the latest data (approximately
30e35 weeks2). This might be attributable to both the poor general
status of our elderly patient population and the fact that only one
third of them were actually treated with targeted agents.
Response to treatment lessened as the treatment lines pro-
gressed (partial response of 30%, 10% and 10%, from evaluated pa-
tients). The reported response to ﬁrst-line treatments is usually
higher for the general patient population (>40%1,2) than the cohort
in this study, suggesting a reduced beneﬁt among elderly patients
when evaluated in isolation. The question of whether there is a
beneﬁt for combination chemotherapy was recently raised by data
that reviewed the treatment of elderly patients in both adjuvant
and metastatic settings. Sargent et al3 showed that adjuvant 5-
ﬂuorouracil (5FU)-based chemotherapy was an effective adjuvant
treatment in elderly patients as well as in younger patients, how-
ever, recent publications have raised some concerns regarding
administering adjuvant treatments to elderly patients. One of them,
the QUick and Simple And Reliable (QUASAR) trial subset analysis
of Stage 2 patients, clearly showed no treatment beneﬁt of adjuvant
5FU among elderly patients.12 The Multicenter International Study
of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment
of Colon Cancer (MOSAIC) trial, in which the adjuvant folinic acid,
5FU, and oxaliplatin (FOLFOX) was compared with 5FU, showed an
overall survival advantage for FOLFOX among the elderly patients
until the 4th year of follow up, however, this advantage was lost
after a longer follow up.13 Another trial, in which the adjuvant
XELOX (xeloda, oxaliplatin) was compared with 5FU, also demon-
strated a questionable beneﬁcial effect of adjuvant treatment in
older patients in a subset analysis.14 The Adjuvant Colon Cancer End
Points (ACCENT) meta-analysis clearly demonstrated no beneﬁcial
effect of combination adjuvant chemotherapy among 2170 patients
who were aged  70 years, even for those in the third stage of
disease.4 As for treatment of elderly MCRC patients with targeted
agents, one recent subset analysis of the Cetuximab Combined with
Irinotecan in First-line Therapy for Metastatic Colorectal Cancer
(CRYSTAL) trial, in which ﬁrst-line treatment with folinic acid, 5FU,
and irinotecan (FOLFIRI) was compared with FOLFIRI þ cetuximab,
showed no signiﬁcant beneﬁt in adding cetuximab to patients who
were aged  70 years.15
Only 14% of our patients who received third-line treatments
experienced any symptomatic relief. By contrast, a large proportion
of these patients had treatment-related side effects (mainly
weakness, diarrhea, and neutropenia). At least one treatment delay,
mainly due to general deterioration or bone marrow toxicity
(neutropenia or thrombocytopenia), was required in 15 patients
(44%). The same number of patients also required dose reduction,
mainly due to weakness and diarrhea. These large gaps between
low rates of symptomatic relief and high rates of toxicity are
worrisome, given that the main goal of treatment in this setting is
palliative care.
Our ﬁnding that the overall survival rate correlates with the
number of treatment lines was expected. This correlation was also
well-described by Grothey et al.1 Likewise, the lack of any corre-
lation between the combinations and sequences of treatments and
overall survival had been described by Tournigand et al.25. Conclusion
The treatment of elderly MCRC patients with third-line
chemotherapy was associated with only a minor clinical response
but with a considerable number of serious side effects. Thus,
treatment should be adjusted for this special population before
proceeding to further lines of treatment, especially after the failure
of the ﬁrst-line chemotherapy treatment.Conﬂicts of interest
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